Current Status of Treg Therapy in Transplantation and Autoimmune Disease
Immunology · 2026
DOI: 10.1111/imm.70151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, 2026. Verfasst von Hongwen Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatovenereology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Autoimmune Diseases, Graft vs Host Disease, Organ Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shenzhen Postdoctoral Research Funding.
Abstract (Originalsprache)
Regulatory T cells (Tregs) represent a critical subset of T lymphocytes essential for maintaining immune homeostasis. Through diverse molecular mechanisms, Tregs exert potent immunosuppressive effects that preserve self‐tolerance and mitigate aberrant immune activation. Dysregulation in Treg frequency or function is closely associated with the development of various immune‐mediated disorders. This has prompted extensive preclinical investigations and clinical trials evaluating the therapeutic potential of Tregs in conditions such as graft‐versus‐host disease, solid organ transplantation, and autoimmune diseases, which have yielded promising outcomes. This review provides a comprehensive overview of current preclinical and clinical applications of Treg‐based therapies, including adoptive Treg transfer, low‐dose IL‐2, and CAR‐Treg therapy, and discusses their effectiveness in modulating immune responses across diverse pathological contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatovenereology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
- Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
- Guangzhou Medical Research Institute of Infectious Diseases, Guangzhou, China.
ORCID-Profile: Hongwen Li
Förderung
- Shenzhen Postdoctoral Research Funding
Zitieren
APA
Li, H., & Zeng, H. (2026). Current Status of Treg Therapy in Transplantation and Autoimmune Disease. Immunology. https://doi.org/10.1111/imm.70151
Vancouver
Li H, Zeng H. Current Status of Treg Therapy in Transplantation and Autoimmune Disease. Immunology. 2026. doi:10.1111/imm.70151
BibTeX
@article{Li2026,
author = {Li, Hongwen and Zeng, Huimin},
title = {Current Status of Treg Therapy in Transplantation and Autoimmune Disease},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70151}
}
EUVIMED